Bibliography
- Brewer GJ, Dick RD, Yuzbasiyan-Gurkan V, et al. Initial therapy of patients with Wilson's disease with tetrathiomolybdate. Arch Neurol 1991;48:42-7
- Brewer GJ, Dick RD, Johnson V, et al. Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients. Arch Neurol 1994;51:545-54
- Brewer GJ, Johnson V, Dick RD, et al. Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 1996;53:1017-25
- Brewer GJ, Hedera P, Kluin KJ, et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 2003;60:379-85
- Brewer GJ, Askari F, Lorincz MT, et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol 2006;63:521-7
- Scheinberg IH, Sternlieb I. Wilson's disease. In: Smith LHJ, editor. Major problems in internal medicine. Philadelphia: WB Saunders; 1984. p 1-171
- Brewer GJ. Wilson's disease: a clinician's guide to recognition, diagnosis, and management. Boston: Kluwer Academic Publishers; 2001
- Brewer GJ. Wilson's disease. In: Fauci AS, Braunward E, Kasper DL, et al, editors. Harrison's principles of internal medicine, 17th edition. New York: McGraw-Hill; 2008. p. 2449-52
- Walshe JM. Penicillamine, a new oral therapy for Wilson's disease. Am J Med 1956;21:487-95
- Walshe JM. Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride. Lancet 1982;1:643-7
- Brewer GJ, Terry CA, Aisen AM, et al. Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. Arch Neurol 1987;44:490-3
- Brewer GJ, Dick RD, Johnson VD, et al. Treatment of Wilson's disease with zinc: XV long-term follow-up studies. J Lab Clin Med 1998;132:264-78
- Brewer GJ, Ullenbruch MR, Dick RB, et al. Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice. J Lab Clin Med 2003;141:210-16
- Brewer GJ, Dick R, Ullenbruch MR, et al. Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis. J Inorg Biochem 2004;98:2160-7
- Askari FK, Dick RB, Mao M, et al. Tetrathiomolybdate therapy protects against concanavalin A and carbon tetrachloride hepatic damage in mice. Exp Bio Med 2004;229:857-63
- Song M, Song Z, Barve S, et al. Tetrathiomolybdate protects against bile duct ligation-induced cholestatic liver injury and fibrosis. J Pharmacol Exp Ther 2008;325:409-16
- Ma S, Hou G, Dick RD, et al. Tetrathiomolybdate protects against liver injury from acetaminophen in mice. J Appl Res Clin Exp Ther 2004;4:419-26
- Hou G, Dick R, Abrams GD, et al. Tetrathiomolybdate protects against cardiac damage by doxorubicin in mice. J Lab Clin Med 2005;146:299-303
- McCubbin MD, Hou G, Abrams GD, et al. Tetrathiomolybdate is effective in a mouse model of arthritis. J Rheumatol 2006;33:2501-6
- Brewer GJ, Dick R, Zeng C, et al. The use of tetrathiomolybdate in treating fibrotic, inflammatory, and autoimmune diseases, including the non-obese diabetic mouse model. J Inorg Biochem 2006;100:927-30
- Hou G, Abrams G, Dick R, et al. Efficacy of tetrathiomolybdate in a mouse model of multiple sclerosis. Transl Res 2008;152:239-44
- Pan Q, Bao LW, Merajver SD. Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFkappaB signaling cascade. Mol Cancer Res 2003;1:701-6
- Pan Q, Kleer CG, van Golen KL, et al. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res 2002;62:4854-9
- Cox C, Merajver SD, Yoo S, et al. Inhibition of the growth of squamous cell carcinoma by tetrathiomolybdate-induced copper suppression in a murine model. Arch Otolaryngol Head Neck Surg 2003;129:781-5
- Cox CD, Teknos TN, Barrios M, et al. The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma. Laryngoscope 2001;111:696-701
- Kent MS, Madewell BR, Dank G, et al. An anticopper antiangiogenic approach for advanced cancer in spontaneously occurring tumors, using tetrathiomolybdate: A pilot study in a canine animal mode. J Trace Elem Exp Med 2004;17:9-20
- Hassouneh B, Islam M, Nagel T, et al. Tetrathiomolybdate promotes tumor necrosis and prevents distant metastases by suppressing angiogenesis in head and neck cancer. Mol Cancer Res 2007;6:1039-45
- Brewer GJ, Dick RD, Grover DK, et al. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res 2000;6:1-10
- Redman BG, Esper P, Pan Q, et al. Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res 2003;9:1666-72
- Henry NL, Dunn R, Merjaver S, et al. Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone refractory prostate cancer. Oncology 2006;71:168-75
- Pass HI, Brewer GJ, Dick R, et al. A Phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results. Ann Thorac Surg 2008;86:383-9
- Gartner EM, Griffith KA, Pan Q, et al. A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer. Invest New Drugs 2008
- Tian XL, Yao W, Guo ZJ, et al. Low dose pirfenidone suppresses transforming growth factor beta-1 and tissue inhibitor of metalloproteinase-1, and protects rats from lung fibrosis induced by bleomycina. Chin Med Sci J 2006;21:145-51
- Lindor K. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. N Engl J Med 2007;357:1524-9
- Shanahan JC, St Clair W. Tumor necrosis factor-alpha blockade: a novel therapy for rheumatic disease. Clin Immunol 2002;103:231-42
- D'Haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999;116:1029-34
- Ogilvie AL, Antoni C, Dechant C, et al. Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 2001;144:587-9
- Brewer GJ. Copper lowering therapy with tetrathiomolybdate produces antiangiogenic, anticancer, antifibrotic and antiinflammatory effects. Semin Integr Med 2003;1:181-90
- Breitkreutz I, Anderson KC. Thalidomide in multiple myeloma–clinical trials and aspects of drug metabolism and toxicity. Expert Opin Drug Metab Toxicol 2008;4:973-85
- Harousseau JL. New treatments in multiple myeloma: beyond optimal treatment. Ann Oncol 2008;19(Suppl 5):v68-70
- Raza A, Mehdi M, Mumtaz M, et al. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia. Cancer 2008;113:1596-604
- Hideshima T, Raje N, Richardson PG, et al. A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma. Ther Clin Risk Manag 2008;4:129-36
- McCormack PL, Keam SJ. Spotlight on bevacizumab in metastatic colorectal cancer. BioDrugs 2008;22:339-41
- Birk D, Barbato J, Mureebe L, et al. Current insights on the biology and clinical aspects of VEGF regulation. Vasc Endovascular Surg 2008 [Epub ahead of print]
- Mills CF, El-Gallad TT, Bremner I. Effects of molybdate, sulfide, and tetrathiomolybdate on copper metabolism in rats. J Inorg Biochem 1981;14:189-207
- Bremner I, Mills CF, Young BW. Copper metabolism in rats given di- or trithiomolybdates. J Inorg Biochem 1982;16:109-19
- Mills CF, El-Gallad TT, Bremner I, et al. Copper and molybdenum absorption by rats given ammonium tetrathiomolybdate. J Inorg Biochem 1981;14:163-75
- Gooneratne SR, Howell JM, Gawthorne JM. An investigation of the effects of intravenous administration of thiomolybdate on copper metabolism in chronic Cu-poisoned sheep. Br J Nutr 1981;46:469-80
- Gooneratne SR, Christensen DA. Effect of chelating agents on the excretion of copper, zinc and iron in the bile and urine of sheep. Vet J 1997;153:171-8
- Ogra Y, Ohmichi M, Suzuki KT. Systemic dispositions of molybdenum and copper after tetrathiomolybdate injection in LEC rats. J Trace Elem Med Bio 1995;9:165-9
- Sugawara N, Lai YR, Sugawara C. Therapeutic effects of tetrathiomolybdate on hepatic dysfunction occurring naturally in Long-Evans Cinnamon (LEC) rats: a bona fide animal model for Wilson's disease. Res Commun Mol Pathol Pharmacol 1999;103:177-87
- Omoto A, Kawahito Y, Prudovsky I, et al. Copper chelation with tetrathiomolybdate suppresses adjuvant-induced arthritis and inflammation-associated cachexia in rats. Arthritis Res Ther 2005;7:R1174-82 [Epub 2005 Aug 8]
- van Golen KL, Bao L, Brewer GJ, et al. Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma. Neoplasia 2002;4:373-9
- Elner SG, Elner VM, Yoshida A, et al. Effects of tetrathiomolybdate in a mouse model of retinal neovascularization. Invest Ophthalmol Vis Sci 2005;46:299-303
- Huang X, Atwood CS, Hartshorn MA, et al. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 1999;38:7609-16
- Multhaup G, Schlicksupp A, Hesse L, et al. The amyloid precursor protein of Alzheimer's disease in the reduction of copper(II) to copper(I). Science 1996;271:1406-9
- Angeletti B, Waldron KJ, Freeman KB, et al. BACE1 cytoplasmic domain interacts with the copper chaperone for superoxide dismutase-1 and binds copper. J Biol Chem 2005;280:17930-7
- Ma Q, Li Y, Du J, et al. Copper binding properties of a tau peptide associated with Alzheimer's disease studied by CD, NMR, and MALDI-TOF MS. Peptides 2006;27:841-9
- Sparks DL, Schreurs BG. Trace amounts of copper in water induce beta-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease. Proc Natl Acad Sci USA 2003;100:11065-9
- Squitti R, Pasqualetti P, Dal Forno G, et al. Excess of serum copper not related to ceruloplasmin in Alzheimer disease. Neurology 2005;64:1040-6
- Adlard PA, Cherny RA, Finkelstein DI, et al. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 2008;59:43-55
- Wadsworth TL, Bishop JA, Domes CM, et al. Copper complexing with tetrathiomolybdate in a murine model of Alzheimer's Disease. Society for Neuroscience Annual Meeting, San Diego, CA; 2007
- Flaherty KR, Arenberg DA, White ES, et al. Treatment of idiopathic pulmonary fibrosis with tetrathiomolybdate. Submitted for publication
- Brewer GJ, Merajver SD. Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper – a review. Integr Cancer Ther 2002;1:327-37
- Vine AK, Brewer GJ. Tetrathiomolybdate as an antiangiogenesis therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration. Trans Am Ophthalmol Soc 2002;100:73-76
- Squitti R, Rossini PM, Cassetta E, et al. d-penicillamine reduces serum oxidative stress in Alzheimer's disease patients. Eur J Clin Invest 2002;32:51-59
- Haywood S, Dincer Z, Jasani B, et al. Molybdenum-associated pituitary endocrinopathy in sheep treated with ammonium tetrathiomolybdate. J Comp Pathol 2004;130:21-31
- Ke Y, Symonds HW. The effect of molybdenum compounts on the biliary excretion of copper by sheep. Proc Nutr Soc 1987;46:69a
- Mason J, Lamand M, Tressol JC, et al. Studies of the changes in systemic copper metabolism and excretion produced by the intravenous administration of trithiomolybdate in sheep. Br J Nutr 1988;59:289-300
- Humphries WR, Mills CF, Greig A, et al. Use of ammonium tetrathiomolybdate in the treatment of copper poisoning in sheep. Vet Rec 1986;119:596-8
- Humphries WR, Morrice PC, Bremner I. A convenient method for the treatment of chronic copper poisoning in sheep using subcutaneous ammonium tetrathiomolybdate. Vet Rec 1988;123:51-3
- Medici V, Trevisan CP, Bigotto MA, et al. Adverse reaction after tetrathiomolybdate treatment for Wilson's disease: a case report. Mov Disord 2006;21:2030-2